♟ Time to Play This Massive Winner Again?

The Greatest Trade in War Room History: Part II [Trade of the Day Logo] [Biogen Hero Image]( ["In at $25.50; out at $135.50 (held for less than four months). $11,000 profit on a single contract. Thank you, Bryan! More than paid for my lifetime membership!" - Ron B., War Room Member]( Bryan Bottarelli, Head Trade Tactician, Monument Traders Alliance [Bryan Bottarelli] It might be time to play one of our biggest winners again. Here's the situation... As longtime Trade of the Day Plus members know, one of our best trades ever was on Biogen (Nasdaq: BIIB). As a quick refresher, in early 2021, Biogen was scheduled to report major FDA approval news on Aduhelm, one of the biggest breakthrough Alzheimer's drugs in the world. Going into the FDA announcement, I speculated that positive news could send the shares soaring up to $400, while negative news could send them plummeting below $100. With major volatility on both sides, Biogen was set up perfectly for a strangle trade. We entered both calls and puts leading into the announcement. As it turned out, the FDA approved Biogen's treatment. And as predicted, the stock blasted above $400 per share on June 7, 2021. [Up to 512% in 24 Hours... Three Quarters in a Row?!]( [Supply Chain Problem Solver]( These fantastic 24-hour gains are 100% confirmed. And starting this earnings season... you could have a shot at gains like these... quarter after quarter... year after year. [>> Get the Details HERE.]( This explosive upside move allowed us to hit a major, major winner. Fast forward to today... Ever since we closed that trade and locked in huge gains, the drama for Biogen has continued. The FDA revised its data, insurance companies announced that they would not cover the treatment, and on May 3, 2022, Biogen ended its efforts to sell Aduhelm. But now, as you read this, Biogen is getting one final crack at the untapped Alzheimer's market, which could be worth upward of $20 billion per year in the U.S. alone. By January 2023, Biogen will announce the results of a trial designed to test whether the latest version of its Alzheimer's drug - which is now called Lecanemab - can slow the progress of the disease in early-stage patients. A 35% reduction of symptoms would be considered a home run result. Anything less would be viewed as yet another major disappointment. [Chart - Biogen Performance] [Logo] YOUR ACTION PLAN In my view, this announcement is Biogen's last hope at remaining a functioning biotech company. If Lecanemab proves to be ineffective, Biogen would have to begin selling off pieces of the company. However, if the drug proves to be effective, Biogen could once again be a world-class biotech company. From a trading perspective, this situation once again sets up very nicely for a two-sided options play. To find out exactly what position to take, join us inside [The War Room](. With such an explosively powerful move possible - in either direction - I simply cannot reveal the exact details of this trade to anyone but paid subscribers. This trade represents the perfect time to join the War Room community. As member Ron B. said above, by playing just one contract, he made $11K off our earlier Biogen trade - more than double the price of a lifetime membership. In other words, you can make one trade and pay for a lifetime membership. [I cannot think of a better reason to join us. Click here to start today.]( [Never Be on the Wrong Side of a Crypto Trade Again??]( If you've tried - and failed - to make money in crypto, you need to check this out. A Wall Street icon-turned-crypto virtuoso is blowing the lid off a phenomenon that appears before virtually every big "moonshot." If you're sick and tired of sitting on the sidelines while literally 100,000 people have become millionaires with crypto, [THIS is what you've been waiting for](... [Chart] MONDAY MARKET MINUTE - Recession Fears Amplify. Two-thirds of all recessions in history have started when the Fed raised interest rates faster than the economy could handle. As that fact sunk in last Friday, the major market averages hit new lows on the year. We'll continue to bias our trades to the downside while also positioning for safe havens. Tracking. - Heat Waves, Storms, Rolling Blackouts and Hurricanes. One of Karim's best Trade of the Day Plus picks this year was Generac (NYSE: GNRC), which Barron's now believes could go up 50% from its lows. The backup power generator company is in a dominant position, but there's still plenty of growth ahead. - Premarket Game on Swole. Planet Fitness (NYSE: PLNT) was up 3% before the opening bell after Raymond James analyst Joseph Altobello upgraded the stock from "Market Perform" to "Strong Buy" and set a $70 price target. INSIGHTS YOU MAY HAVE MISSED [Alttext]( [The No. 1 Trading System That Let Me Quit My 9-to-5]( [Investment Plummeting]( [Can You Pick a Losing Tech Stock? If So, You Could Make...]( [Classic Value Buy]( [This Is a Classic Value Buy]( [Trading Hacks for Beginners]( [Top 3 Trading Hacks for Beginners]( [Instagram]( [Follow Us on Instagram!]( [FACEBOOK]( [TWITTER]( [Monument Traders Alliance] Monument Traders Alliance You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, [click here](. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 16 West Madison Street | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 [Website]( | [Privacy Policy]( Keep the emails you value from falling into your spam folder. [Whitelist Trade of the Day](. © 2022 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.